Reflections on ICER’s Process

At the conclusion of the July 15, 2016 meeting on obeticholic acid, the policy roundtable participants reflected on their experience with ICER’s process and the importance of bringing conversations about drug pricing and coverage into a public forum. The roundtable was composed of subject matter experts representing a variety of perspectives, including a patient, clinical experts, a drug manufacturer, and payers. Hear what they had to say in this short video.

Policy Roundtable Reflections: July 15, 2016 Meeting

Uploaded by Institute for Clinical and Economic Review ICER on 2016-08-02.

Participants (in order of appearance):

Barbara Henry, RPh, Senior Clinical Pharmacy Coordinator, Harvard Pilgrim Health Care

Judith Donovan, Patient with PBC

Daniel Pratt, MD, Clinical Director, Liver Transplantation; Director, Autoimmune & Cholestatic Liver Center, Massachusetts General Hospital

Kathleen Corey, MD, MPH, Director, MGH Fatty Liver Clinic, MGH Gastrointestinal Unit, Massachusetts General Hospital

Juan Carlos Lopez-Talavera, MD, PhD, Senior Vice President of Medical Affairs, Intercept Pharmaceuticals

Tom Simpatico, MD, Chief Medical Officer, Department of Vermont Health Access